Research programme: engineered T-cell therapies - Triumvira Immunologics
Latest Information Update: 28 Oct 2022
At a glance
- Originator Triumvira
- Developer Triumvira; University of Toronto
- Class Immunotherapies; T lymphocyte cell therapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Oct 2022 No recent reports of development identified for research development in Cancer in Canada (Parenteral)
- 20 Feb 2019 Knight Therapeutics granted market license for engineered T-cell therapies in Canada, Israel, Mexico, Colombia
- 10 Sep 2018 Triumvira Immunologics and University of Toronto agree to develop antibodies for engineered T cells for Cancer